VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) — AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is pleased to provide this corporate update on the Company’s activities and progress in the first five months of 2022, as well as an outlook on the Company’s objectives and expectations for the balance of the year.

“At the beginning of the year, we laid out a plan to expand our point-of-care testing platform in pharmacies across Canada and beyond and begin to generate more substantial revenues,” said Hector Bremner, CEO of Avricore Health Inc. “Our progress towards those objectives has been significant, and we are very confident in our current client negotiations and planning.”
Staying Focused
Since March of 2020, every business has been thrust into a series of complex, unpredictable situations that have required adaptation, innovation, and a discipline to remain focused on key objectives. One impact on the Company’s objective with respect to expanding HealthTab™, the proprietary platform for offering point-of care service offering in community pharmacies, has been the COVID-19 pandemic.
Pharmacy was a source of primary care and vaccinations for millions of Canadians, however since the first quarter of this year, public health policies have shifted, lifting some of the pressure on pharmacists of those activities. But there is still a large demand from patients as they struggle to access a family physician to support them with their concerns, particularly around diabetes and heart disease.
What you need to know: Because of a focused determination and discipline of the Company and the HealthTab™ team, the pilot project announced with Shoppers Drug Mart® was successfully executed, despite operating under the extraordinary impacts of the pandemic. There have been incremental increases in the number of locations under this program, taking the current count to 53 locations actively operating HealthTab™ connected Abbott Afinion 2™ instruments across Ontario and British Columbia.
The Company is in discussions with multiple pharmacy groups to expand the Canadian and International HealthTab™ network.
Fiscal Discipline / Revenues Growing
The Company is pleased with the overall performance of the balance sheet, taking it from a high-liability / low-asset scenario to reversing those figures in just two fiscal years with working capital of $1.94 million as of March 31, 2022 – and those two years were during some of the most challenging business periods on record.
The most recent financials demonstrated that fiscal 2021 saw a year-over-year 372% increase in revenues and the Company has maintained strong fiscal discipline, maintaining a moderate operating cost model, conserving cash, and limiting exposure to further equity dilution while executing on the build out of HealthTab™.
Product Development
The Company’s team has had the opportunity to test, develop and deploy several system improvements, which has increased HealthTab™’s reporting capabilities, accuracy, improved reliability as well as enhancing pharmacist and patient user experience.    
Actions have included successfully launching a fully upgraded platform (HT 2.0), enhanced security for integration partners, more flexible reporting options, manual antigen tracking via Abbott ID Now™ integration, developed sector leading QA program all while managing software development costs.
Next Steps
At the beginning of this year, the Company laid out for shareholders and the public the key objectives for the year, here is the status of these specific items:

2022 Objectives

Concluding the scale up agreement and plan, which will include data integration with key digital partners
In progress with anticipated conclusion in Q3 2022

Expansion of HT in other pharmacy groups in Canada

In progress, new pilot/adoption programs in Q3 2022

Securing an initial US pharmacy customer

Q4 2022

Launching the UK expansion (pushing into EU)

Multiple project opportunities in discussion, Q4 2022

Securing further Abbott agreements in US, UK, EU, etc.
In progress, expected by Q3
Hiring key positions to support technical and business development efforts
Actively hiring to support expansion

Revenues and profitability!

With the anticipated growth and strong fiscal management in 2022, the Company sees itself as cash-flow positive by Q3 2023
The balance of the year will be focused on successfully concluding the business development and expansion opportunities which are currently being investigated.
HealthTab™ Market Fast Facts
Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it’s only after a heart attack they are diagnosed. (Source)
There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.
Avricore Health Inc.                                        
Hector Bremner, CEO 604-773-8943         
[email protected]                                                             
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.

Related Quotes
Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk posted in a thread on Twitter (NYSE: TWTR) in March, after inflation hit a 40-year high for the first time this year, advising followers to own “physical things” when inflation is high. In the tweet, Musk said “As a general principle, for those looking for advice from this thread, it is generally better to own physical things like a home or stock in companies you think make good products, than dollars when inflation is high. I still own & won’t sell my Bit
The rate of U.S. inflation reached a 40-year high of 8.6% in May as overall prices for things including rent, gas and food all remain on the rise. “I personally believe that this inflation is here to stay for quite some time,” Orman recently told CNBC, prior to the release of May’s CPI data from the U.S. Bureau of Labor Statistics. The first is a fixed rate when the purchaser buys the bond, and the second is the inflation adjustment rate, which is reset every six months based on inflation.
Your retirement savings are $1 million. You want $100,000 of yearly retirement income, including Social Security. Is that doable without tons of risk?
Nobody knows when a stock (or the stock market) has hit bottom. People can speculate — and every analyst hoping for a little bit of television fame most certainly will — but no person, no matter how many past predictions they claim to have gotten right knows when a stock or the market has fallen as low as it will go. Down markets, bear markets, market crashes — whatever you want to call them follow no rules.
(Bloomberg) — When the nineties ended, an overvalued stock market took three long years to rid itself of its accumulated excess in what is now known as the dot-com crash.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingRetailers Should Heed Target’s Cautionary TaleGen Z, Millennials and Gen X All Basically Agree on WFHThat a similar recko
Friday’s consumer-price index report for May — which showed the annual headline U.S. inflation rate climbing to 8.6% in May, with few signs of having peaked — is boosting the chances of a jumbo-sized rate increase by monetary-policy makers as soon as next week, and eliciting dire warnings that central bankers have completely lost control of prices. Fed funds futures traders now see a 21% chance of a 75-basis-point hike in June, up from just 3.6% on Thursday, according to the CME FedWatch Tool. Beneath the issue of where the Fed goes from here is a much more fundamental and serious problem: Some observers fear the U.S. central bank has already effectively lost control of inflation.
Worried about inflation? You should be — especially if you own the wrong assets and bet against S&P 500 and growth stocks.
(Bloomberg) — Treasury traders are throwing down the gauntlet to a Federal Reserve that’s fallen further behind in its fight to cool the hottest inflation in four decades.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingRetailers Should Heed Target’s Cautionary TaleGen Z, Millennials and Gen X All Basically Agree on WFHA bruising bond sel
When searching for great dividend stocks, there is a wide variety of factors to consider. Among them are earnings durability, recession resilience, dividend safety, and competitive advantages. Canadian stocks listed in the US tend to be undervalued relative to industry peers based in the US, and that not only means the margin of safety is better for the shareholder, but dividend yields are higher as well.
Electric vehicle maker says it wants to go forward with plans for another stock split, but there's something that has to happen first.
The biggest losers in the stock market include DocuSign, PayPal, Netflix and Zoom Video Communications.
What to do in today’s market? The last few trading sessions of declining stocks would seem to indicate that the late-May rally we saw has run its course. But that doesn’t mean the opportunities for buy-minded investors are all gone. The recent declines, and the overall downward trend we’ve seen year-to-date, have left many fundamentally sound stocks trading at rock bottom prices. And that may have created an opportunity for investors willing do a bit of bottom fishing. The trick for investors, h
For the second time in three years, Tesla will split its stock, lowering its price and increasing the number of shares outstanding.
After climbing more than 60% this year, energy stocks still have room to run. Six picks in the industry’s most promising areas.
The Nasdaq closed below the low of its follow-through day, one of many bearish signals this past week. Here's what to do.
“Ball of confusion, that's what the world is today,” sang the Temptations on their 1970 classic, a sentiment which can readily apply to the stock market’s present state. It’s hard to get a grip on the market’s choppy action in 2022 and investors could use a clear signal to follow when considering a new investment. One way to get a head start is by tracking the moves of the insiders. These are the corporate officers with in-depth knowledge of the companies they helm. To keep the playing field lev
The U.S. hasn't yet entered a recession — which is officially defined as two consecutive quarters of negative GDP growth — but runaway inflation, stagnant wages, food shortages, rising interest rates, and geopolitical turmoil could all break this fragile economy's back in the near future. If that happens, growth stocks will fall further as value stocks become even more attractive. Altria is the top tobacco company in America.
Industrial giant 3M's (NYSE: MMM) stock is now yielding more than 4% and is very tempting for income-seeking investors. On the first-quarter earnings call, management left its full-year guidance unchanged despite revealing a host of headwinds. For example, it said 3M was making a slow start to the quarter.
(Bloomberg) — All of a sudden, the market’s back in “good-news-is-bad-news” mode. Any positive readings on the economy, particularly those on employment and inflation, can be interpreted as signals that the Federal Reserve will have to stay aggressive with its rate hiking regime. Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingRetailers
DocuSign (NASDAQ: DOCU) stock plunged 23% during the after-hours session on June 9 following the release of its first-quarter earnings report. The e-signature and contract management services provider reported revenue growth of 25% year over year to $588.


Published On: June 12, 2022 / Categories: Uncategorized /

Subscribe To Receive The Latest News

Stay upto date with latest developments

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

Add notice about your Privacy Policy here.